WO2010062144A3 - 에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법 - Google Patents

에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법 Download PDF

Info

Publication number
WO2010062144A3
WO2010062144A3 PCT/KR2009/007057 KR2009007057W WO2010062144A3 WO 2010062144 A3 WO2010062144 A3 WO 2010062144A3 KR 2009007057 W KR2009007057 W KR 2009007057W WO 2010062144 A3 WO2010062144 A3 WO 2010062144A3
Authority
WO
WIPO (PCT)
Prior art keywords
transglutaminase
ethacrynic acid
pharmaceutically acceptable
acceptable salt
inhibitor
Prior art date
Application number
PCT/KR2009/007057
Other languages
English (en)
French (fr)
Other versions
WO2010062144A2 (ko
Inventor
김수열
이창훈
이병일
정경채
Original Assignee
국립암센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 국립암센터 filed Critical 국립암센터
Priority to US12/920,406 priority Critical patent/US20110288176A1/en
Publication of WO2010062144A2 publication Critical patent/WO2010062144A2/ko
Publication of WO2010062144A3 publication Critical patent/WO2010062144A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 에타크리닉 산 및 그의 약제학적으로 허용가능한 염을 포함하는 트란스글루타미나제 억제제에 관한 것으로, 더욱 상세하게는 이상 발현의 경우 질병의 병리적 기전에 관여하는 트란스글루타미나제의 작용을 억제하기 위한 에타크리닉 산, 그의 약제학적으로 허용가능한 염을 포함하는 트란스글루타미나제 억제제와 이들의 신규한 용도에 관한 것이다. 본 발명에 따르면, 에타크리닉 산, 그의 약제학적으로 허용가능한 염의 활성성분을 포함하는 것을 특징으로 하는 트란스글루타미나제 억제제 및 트란스글루타미나제의 억제방법을 제공할 수 있다. 본 발명에 따른 에타크리닉 산, 그의 약제학적으로 허용가능한 염 또는 그를 포함하는 트란스글루타미나제 억제제 및 그를 이용한 트란스글루타미나제 억제 방법은 트란스글루타미나제가 이상 발현되는 질환을 가진 대상에게 안전한 방법으로 부작용없이 용이하게 적용되어 트란스글루타미나제를 억제하는 효과를 얻을 수 있다.
PCT/KR2009/007057 2008-11-27 2009-11-27 에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법 WO2010062144A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/920,406 US20110288176A1 (en) 2008-11-27 2009-11-27 Ethacrynic acid-containing composition for prevention or treatment of transglutaminase-related diseases and method for prevention or treatment of transglutaminase-related diseases using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0118688 2008-11-27
KR1020080118688A KR20100060189A (ko) 2008-11-27 2008-11-27 에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법

Publications (2)

Publication Number Publication Date
WO2010062144A2 WO2010062144A2 (ko) 2010-06-03
WO2010062144A3 true WO2010062144A3 (ko) 2010-08-19

Family

ID=42226278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/007057 WO2010062144A2 (ko) 2008-11-27 2009-11-27 에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법

Country Status (3)

Country Link
US (1) US20110288176A1 (ko)
KR (1) KR20100060189A (ko)
WO (1) WO2010062144A2 (ko)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2007128158A1 (en) * 2006-05-09 2007-11-15 Ecole Polytechnique Federale De Lausanne (Epfl) Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
PT2038252T (pt) * 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2007128158A1 (en) * 2006-05-09 2007-11-15 Ecole Polytechnique Federale De Lausanne (Epfl) Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, RUI ET AL.: "Ethacrynic Acid Butyl-Ester Induces Apoptosis in Leukemi a Cells through a Hydrogen Peroxide-Mediated Pathway Independent of Glutathi on S-Transferase P1-1 Inhibition", CANCER RESEARCH, vol. 67, no. 16, 2007, pages 7856 - 7864 *

Also Published As

Publication number Publication date
KR20100060189A (ko) 2010-06-07
WO2010062144A2 (ko) 2010-06-03
US20110288176A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
IL203448A (en) History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them
WO2008088030A1 (ja) 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
WO2011058474A8 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
WO2010032875A3 (en) Heterocyclic carboxamide compounds
MX2012000766A (es) Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.
WO2008033562A3 (en) Kinase inhibitor compounds
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007101232A3 (en) Inhibition of jak2 as a treatment of pulmonary arterial hypertension
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2009145456A3 (ko) 헤테로사이클 유도체
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
MA32240B1 (fr) Inhibiteurs de désacétylases b à base d'hydroxamate
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2008153318A3 (en) Transglutaminase inhibitor comprising chlorogenic acid and a method for producing thereof
WO2007081808A3 (en) Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
EP1909804A4 (en) Glucosamine and derivatives thereof as TG inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09829351

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12920406

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09829351

Country of ref document: EP

Kind code of ref document: A2